Seborrheic Dermatitis

• Malassezia-Mediated Immune Activation: Malassezia species, lipophilic yeasts normally resident on human skin, undergo overgrowth and shift in species composition (notably increased Malassezia globosa and Malassezia restricta) in genetically predisposed individuals. These organisms produce lipid metabolites and proteins that act as pathogen-associated molecular patterns (PAMPs), triggering enhanced innate immune recognition through toll-like receptors (TLR2 and TLR4) on keratinocytes and dendritic cells. This leads to increased production of pro-inflammatory cytokines including TNF-α, IL-6, IL-8, and IL-17, which recruit T cells and neutrophils to affected skin. The organism's oleic acid production directly irritates skin and enhances the inflammatory cascade, while enzymatic degradation of sebaceous lipids generates proinflammatory free fatty acids. This explains why seborrheic dermatitis predominantly affects sebaceous gland-rich areas (scalp, face, upper chest, intertriginous regions) and why clinical severity often correlates with sebum production.

• Impaired Epidermal Barrier Function and Altered Cutaneous Immunity: Affected individuals demonstrate reduced epidermal lipid content, particularly decreased ceramides and free fatty acids compared to unaffected controls, resulting in compromised skin barrier integrity and increased transepidermal water loss (TEWL). This barrier dysfunction permits enhanced penetration of irritants and microbial antigens, creating a permissive environment for Malassezia proliferation. Additionally, seborrheic dermatitis sites show decreased expression of antimicrobial peptides (particularly β-defensins) and reduced langerin+ dendritic cell populations, indicating dysregulated innate immune responses. Paradoxically, despite reduced baseline antimicrobial defenses, affected individuals demonstrate a heightened adaptive Th1 and Th17 T cell response to Malassezia antigens, suggesting a dysbalance between innate and adaptive immunity that favors chronic inflammation while inadequately clearing the organism.

• Lipid Metabolism Dysfunction and Sebum Composition Alterations: Individuals with seborrheic dermatitis demonstrate alterations in sebaceous gland lipid metabolism, with abnormal ratios of saturated to unsaturated fatty acids in sebum and increased oxidative damage to sebaceous lipids. This creates a microenvironment favoring Malassezia species selection and proliferation, as these organisms preferentially colonize sites with specific lipid compositions. The altered lipid environment simultaneously disrupts normal corneocyte adhesion and lipid-dependent barrier proteins, leading to visible scaling and erythema. Genetic variations in genes encoding lipase enzymes and fatty acid metabolism regulators (such as SREBP-1c) contribute to this lipid dysmetabolism, explaining the genetic component of disease susceptibility.

• Additional Inflammatory Mechanisms: Seborrheic dermatitis involves activation of the complement cascade through both classical and alternative pathways, with C5a and C3a anaphylatoxins augmenting chemotaxis of inflammatory cells. Increased levels of substance P (a neuropeptide with neuroimmune functions) in affected skin suggest neurogenic inflammation contributes to disease pathogenesis, potentially explaining exacerbations with stress and the association with neurological diseases. Recent evidence implicates dysbiosis of the skin microbiome beyond just Malassezia, with reduced diversity of beneficial commensals that normally suppress inflammatory responses. Additionally, some evidence suggests a role for fungal antigen cross-reactivity with neural epitopes in patients with Parkinson's disease, explaining the particularly high prevalence (25-80%) of seborrheic dermatitis in this population.

• Genetic Predisposition: Family history is present in approximately 25-30% of patients, indicating heritable susceptibility to the condition. Specific genetic polymorphisms in pattern recognition receptor genes (TLR2, TLR4), antimicrobial peptide genes, and lipid metabolism genes increase disease risk. This genetic component explains both the bimodal age distribution and ethnic variation in prevalence, with higher rates in individuals of Ashkenazi Jewish, Mediterranean, and Northern European descent compared to African and East Asian populations.

• Malassezia Overgrowth and Species Composition: While Malassezia species are normal skin commensals, quantitative overgrowth and alterations in species composition (particularly increased proportion of oleic acid-producing strains) occur in affected individuals. The mechanism driving overgrowth likely involves the combination of genetic predisposition (altered lipid metabolism favoring Malassezia), environmental factors (humidity, temperature), and reduced antimicrobial defenses, with causality suggested by the therapeutic response to anti-Malassezia agents.

• Immunocompromise: HIV/AIDS represents the most clinically significant risk factor for both development and severity of seborrheic dermatitis, with prevalence increasing inversely with CD4+ T cell count. Patients with CD4 counts below 200 cells/μL have dramatically increased incidence and severity, making seborrheic dermatitis a potential marker of advancing immunosuppression. Similarly, patients receiving chronic systemic corticosteroids, those with other immunosuppressive conditions (transplant recipients, patients on biologics), and individuals with severe combined immunodeficiency show increased disease prevalence and severity.

• Neurological Disorders: Parkinson's disease shows one of the strongest epidemiologic associations with seborrheic dermatitis, present in 25-80% of patients depending on disease duration and severity. The mechanism likely involves both sebaceous gland dysfunction from dopaminergic system involvement and potential Malassezia-neural antigen cross-reactivity. Other neurological conditions with increased seborrheic dermatitis prevalence include depression, schizophrenia, and other psychiatric disorders, though causality remains uncertain and may reflect shared neuroimmune mechanisms.

• Environmental and Behavioral Factors: Cold, dry winter climates exacerbate seborrheic dermatitis (contrary to other conditions worsened by humidity), likely through increased barrier dysfunction. Psychological stress consistently triggers or exacerbates disease in susceptible individuals through neuroendocrine mechanisms (increased substance P, altered HPA axis function). Poor hygiene may permit Malassezia overgrowth, while excessive shampooing and harsh detergents paradoxically may worsen disease through barrier disruption. Limited sun exposure (phototherapy is therapeutic) and infrequent exposure to solar UVB radiation support disease progression.

• Other Risk Factors: Male gender (2:1 male predominance in adults), increased sebum production (puberty, androgen excess), increased skin oiliness, and malabsorption states (particularly fat-soluble vitamin deficiency) increase disease risk. Zinc deficiency (whether absolute or functional) predisposes to seborrheic dermatitis, likely through effects on immune function and epithelial integrity.

• Pruritus (Itching): The cardinal symptom in most patients, ranging from mild to intensely bothersome, likely mediated by upregulation of pruriceptors, neuropeptide release (substance P), and inflammatory mediators (histamine, IL-31) in affected skin. Pruritus characteristically waxes and wanes with disease activity and may be exacerbated by stress, sweating, and irritant exposure. Paradoxically, pruritus is often less severe in seborrheic dermatitis compared to other inflammatory dermatoses like atopic dermatitis, though cosmetic concerns frequently cause greater patient distress.

• Burning and Discomfort: Many patients report burning, stinging sensations rather than pure pruritus, reflecting increased irritability of compromised skin and heightened sensory nerve responsiveness. This burning quality is particularly common on the face and intertriginous areas where skin barrier disruption is most pronounced.

• Erythema (Redness): Manifests as ill-defined patches and plaques of salmon-pink to bright red coloration, reflecting underlying vasodilation and inflammatory infiltrate. Erythema is most prominent on the initial presentation and with acute exacerbations; chronic lesions may appear more brown/tan. The erythema blanches with pressure in early disease but may become non-blanching in chronic lesions with increased vascularity.

• Scaling: A hallmark feature consisting of fine, yellow-white, oily, greasy-appearing scale (greasy scale distinguishes it from the dry scale of psoriasis or eczema). Scale distribution directly follows the inflammation and results from accelerated epidermal turnover (7-day cycle versus normal 28 days) with cohesive grouping due to retained sebum. The greasy nature reflects the lipid-rich environment; when scale is removed, the underlying erythematous skin is revealed without significant erosion or excoriation (except where patient has scratched).

• Distribution Pattern: The characteristic distribution to sebaceous gland-rich areas is key to diagnosis, with most common sites including: (1) scalp (most common site, often presenting as cradle cap in infants or dandruff in adults), (2) nasolabial folds and glabella, (3) eyebrows and eyelid margins (seborrheic blepharitis), (4) ears and postauricular regions, (5) upper chest and interscapular region (often in V-pattern), and (6) intertriginous areas (axillae, groin, inframammary folds, intergluteal cleft). This distribution pattern directly correlates with Malassezia density on normal skin, which is highest in these sebaceous-rich areas.

• Physical Examination Findings:
• Salmon-pink erythematous patches and plaques with well-demarcated (though often not sharply defined) borders
• Greasy, adherent, easily removable scale that may appear yellow-white or brown
• Possible excoriation marks from patient scratching, though typically less pronounced than in atopic dermatitis
• Follicular involvement with appearance of folliculitis in some cases (particularly on chest)
• Lack of vesicles, bullae, or pustules (unless secondarily infected)
• Possible seborrheic blepharitis with inflammation of eyelid margins and scale at lash line

• Clinical Variants and Special Presentations:
• Infants (Cradle Cap): Presents in first 2-8 weeks of life as greasy yellow-brown crusted plaques on scalp vertex, may extend to face and intertriginous areas; usually self-limited by 6-12 months but may persist longer
• Seborrheic Blepharitis: Erythema and scale at eyelid margins (especially upper lids), may cause discomfort and watery eyes; can predispose to secondary bacterial infection
• Otitis Externa (Otoseborrheic Dermatitis): Extension into external auditory canal causing itching, scaling, and possible drainage
• Severe Inflammatory Variant: In immunocompromised patients (especially CD4+ <200), may present with confluent erythematous plaques, exudation, and crusting; may resemble psoriasis or other inflammatory conditions
• Seborrheic Dermatitis with Folliculitis: Presentation on chest with follicular pustules and papules, reflecting follicular extension of inflammation
• Facial Dermatitis: Often involves U-shaped distribution (medial face, nasolabial folds, glabella, eyebrows) rather than the V-pattern of upper chest involvement

• Clinical Diagnostic Criteria (based on characteristic presentation):
• Presence of erythematous patches/plaques with greasy (oily) scale
• Characteristic distribution to sebaceous gland-rich areas (scalp, face, intertriginous regions)
• Chronic relapsing course with exacerbations during stress or winter months
• Response to antifungal or anti-inflammatory therapies
• Absence of other systemic features, vesicles, or signs suggesting alternative diagnosis
• No specific severity scoring validated for clinical use, though assessment of extent (percentage of body surface area affected) and impact on function guides management decisions

• History and Associated Features:
• Duration of symptoms (chronic relapsing course typical)
• Relationship to stress, seasons (winter exacerbation common)
• Presence of neurological conditions (Parkinson's disease, depression)
• Immunosuppression status (critical in HIV+ patients for assessing disease severity and CD4 count)
• Medications (corticosteroids, immunosuppressants, antiretrovirals)
• Family history (present in ~25-30%)
• Associated symptoms of pruritus or burning

• Physical Examination Pearls:
• Examine scalp carefully - parting hair in multiple areas to visualize scale; seborrheic dermatitis may appear identical to dandruff (nonsyndromic seborrheic dermatitis)
• Check nasolabial folds and glabella - early facial involvement often begins here before spreading
• Inspect postauricular regions - commonly affected area frequently missed
• Assess for secondary infection - pustules, purulent drainage, or excessive crusting suggest bacterial superinfection (more common in immunocompromised)
• Evaluate eyelid margins - seborrheic blepharitis may be presenting feature
• Examine intertriginous areas - axillae, groin, and inframammary regions frequently involved
• Note greasy vs. dry nature of scale - greasy scale favors seborrheic dermatitis; dry scale suggests psoriasis, eczema, or tinea

• Laboratory Testing (typically not necessary for diagnosis):
• KOH (Potassium Hydroxide) Preparation: While Malassezia can be identified on KOH prep from scale, this is neither sensitive nor specific for seborrheic dermatitis as Malassezia colonizes normal skin; not routinely recommended for diagnosis
• Fungal Culture: Not recommended; Malassezia species are difficult to culture, and culture results do not change management
• Bacterial Culture: Only indicated if secondary bacterial infection suspected (unusual except in immunocompromised patients)
• Histopathology: Rarely indicated but shows perivascular lymphohistiocytic infiltrate in superficial dermis, acanthosis, hyperkeratosis, parakeratosis, and possible presence of Malassezia organisms in follicular ostia; helpful when diagnosis unclear

• Imaging: Not indicated for diagnosis; imaging plays no role in typical presentation

• Differential Diagnosis Considerations (critical for Step 2 CK):
• Psoriasis: Distinguished by presence of silvery scale (not greasy), well-demarcated plaques, Auspitz sign (punctate bleeding when scale removed), typical sites (extensor surfaces, nails), and positive family history in >30%; psoriasis affects palms/soles (seborrheic dermatitis does not) and nail involvement is common
• Atopic Dermatitis (Eczema): More severe pruritus and lichenification, typical childhood onset, personal history of atopy, distribution on antecubital fossae and popliteal fossae (though facial involvement can occur)

Immediate considerations

• Screen for the driver, not just the rash: abrupt-onset, severe, or treatment-refractory disease warrants HIV testing (CDC recommends routine opt-out testing); in HIV, antiretroviral therapy with immune reconstitution is the definitive intervention. Erythroderma or an ill infant is managed as an inpatient problem, not with topicals.

First-line therapy

• Topical azole antifungals: ketoconazole 2% shampoo or cream — reduces Malassezia lipase activity and oleic acid generation, cutting the TLR2/TLR4-driven cytokine response. Used 2x/week on scalp, left on several minutes before rinsing.
• Other antifungal/keratolytic shampoos: selenium sulfide, zinc pyrithione, ciclopirox — cytostatic to the yeast and reduce scale.
• Low-potency topical corticosteroid (hydrocortisone 2.5%) for short courses to control erythema and pruritus; class I–III steroid solutions/foams are acceptable on scalp only, briefly.
• Infantile cradle cap: emollient (mineral oil), soft-brush descaling, gentle shampooing; largely self-limited — reassurance is the answer on exams.

Escalation and second-line

• Topical calcineurin inhibitors: tacrolimus ointment or pimecrolimus cream — steroid-sparing for face/intertriginous skin, avoiding atrophy.
• Topical roflumilast foam (PDE-4 inhibitor) — FDA-approved for seborrheic dermatitis; nonsteroidal option for scalp and body.
• Coal tar or salicylic acid shampoos for thick adherent scale; narrowband UVB for extensive disease.
• Oral antifungals (itraconazole, fluconazole) are reserved for severe, widespread, or refractory disease.

Avoid

• Prolonged mid/high-potency steroids on the face: cause atrophy, telangiectasia, perioral dermatitis and steroid rosacea with rebound flares.
• Oral ketoconazole: FDA restricted for superficial fungal disease because of hepatotoxicity, QT prolongation, and CYP3A4 interactions.
• Systemic corticosteroids: no role; rebound erythroderma follows withdrawal.
• Salicylic acid in infants: percutaneous absorption risks salicylate toxicity.

Complications of the disease

• Secondary bacterial infection (impetiginization): barrier disruption plus excoriation permits Staphylococcus aureus or streptococcal colonization. Signaled by honey-colored crust, pustules, purulent drainage, or new pain and warmth; treat with topical or oral anti-staphylococcal therapy per IDSA skin and soft tissue infection guidance.
• Exfoliative erythroderma: confluent inflammation involving most of the body surface, driven by massive cytokine release and cutaneous vasodilation. Produces high-output fluid and heat loss, hypothermia, hypoalbuminemia, and hemodynamic instability — a dermatologic emergency requiring admission. Most often seen with immunosuppression or after abrupt systemic steroid withdrawal.
• Leiner phenotype in infants: erythroderma with intractable diarrhea, failure to thrive, and recurrent infection; classically linked to complement/immune dysfunction — emergency, prompting immunodeficiency evaluation rather than more shampoo.
• Seborrheic blepharitis with ocular sequelae: meibomian dysfunction and lid-margin inflammation cause evaporative dry eye, chalazion, and rarely marginal keratitis; the finding is persistent burning, crusted lashes, or conjunctival injection — refer to ophthalmology.
• Pigmentary change: post-inflammatory hyperpigmentation or, characteristically in darker skin types, hypopigmented petaloid patches on the face that persist long after erythema resolves.
• Psychosocial morbidity: visible facial and scalp disease drives depression and social withdrawal; chronic scratching may cause lichenification and, rarely, non-scarring hair thinning.
• Marker of systemic disease: explosive or refractory disease may be the first clue to undiagnosed HIV or early Parkinson disease.

Complications of treatment

• Topical corticosteroids: dermal collagen loss produces atrophy, striae, telangiectasia, perioral dermatitis, and steroid rosacea; tachyphylaxis with rebound flare on withdrawal. Facial skin is most vulnerable.
• Topical calcineurin inhibitors: transient burning/stinging from substance P release; carry an FDA boxed warning regarding theoretical malignancy risk.
• Contact dermatitis: propylene glycol and fragrance vehicles cause a sharply bordered, worsening-on-treatment eruption.
• Oral azoles: hepatotoxicity, QT prolongation, and CYP3A4 interactions — check liver enzymes and the medication list.
• Selenium sulfide/tar: scalp irritation, odor, and discoloration of light or chemically treated hair.

• The buzzword triad: greasy, yellow-white scale on salmon-pink patches in the nasolabial folds, glabella, eyebrows, and scalp. Greasy scale = seborrheic dermatitis; silvery scale with Auspitz sign on extensors = psoriasis. Palms, soles, and nails are spared in seborrheic dermatitis.
• The single best next step in severe, sudden, or refractory disease is HIV testing. Extensive seborrheic dermatitis can be the presenting sign of advanced HIV; severity tracks inversely with CD4 count. Definitive treatment in that setting is antiretroviral therapy, not a stronger steroid.
• The association examiners love: Parkinson disease. Reduced facial mobility and autonomic sebum overproduction ("seborrhea") make it common and often precede or accompany motor signs; other dopamine-deficient states and antipsychotic-induced parkinsonism behave similarly.
• Mechanism in one line: Malassezia globosa/restricta lipases liberate oleic acid from sebum → TLR-mediated innate inflammation in sebaceous-rich sites. This is why an antifungal shampoo (ketoconazole 2%) — not an antibiotic — is first-line, and why Malassezia on KOH proves nothing (it colonizes normal skin).
• Infant with cradle cap: reassurance, emollient, gentle brushing. But cradle cap plus petechiae or purpura in the scalp/diaper area, hepatosplenomegaly, lymphadenopathy, or lytic bone lesions means Langerhans cell histiocytosis — biopsy showing CD1a+/S100+ cells with Birbeck granules. Cradle cap plus erythroderma, diarrhea, and failure to thrive means immunodeficiency workup.
• Common distractor — ordering tests. Diagnosis is clinical; KOH, fungal culture, and biopsy are not routine. Reserve biopsy for atypical or non-responding disease.
• Common distractor — potent topical steroids on the face. A mid- or high-potency steroid used chronically on facial skin produces atrophy, telangiectasia, and perioral dermatitis; use low-potency hydrocortisone briefly, or a steroid-sparing topical calcineurin inhibitor for maintenance.
• Course: chronic and relapsing, worse in winter and with stress; infantile disease usually resolves by the first birthday, adult disease requires indefinite intermittent suppressive therapy.